Saltar al contenido
Merck
Todas las fotos(2)

Documentos clave

Ver Toda la documentación

L5918

Sigma-Aldrich

Lomustine

≥98%

Sinónimos:

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):
C9H16ClN3O2
Número de CAS:
13010-47-4
Peso molecular:
233.70
EC Number:
235-859-2
MDL number:
MFCD00012392
UNSPSC Code:
12352100
PubChem Substance ID:
329817632
NACRES:
NA.25

Quality Level

100

assay

≥98%

storage temp.

−20°C

SMILES string

ClCCN(N=O)C(=O)NC1CCCCC1

InChI

1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)

InChI key

GQYIWUVLTXOXAJ-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

hcodes

H301,H350

Hazard Classifications

Acute Tox. 3 Oral - Carc. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
MKCV3653
MKCS6368
MKCL2081
MKCJ4400
MKCJ0518

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

C F Saba et al.
Veterinary and comparative oncology, 10(4), 283-291 (2012-01-13)
Treatment of feline vaccine-associated sarcoma (VAS) is challenging, in part due to the high likelihood of tumour recurrence despite aggressive local therapy. Lomustine is potentially an attractive agent to add to the current treatment armamentarium. In this de-escalating phase I/II
Tracy T Batchelor et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(26), 3212-3218 (2013-08-14)
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy
Greg Yothers et al.
Journal of the National Cancer Institute, 103(20), 1498-1506 (2011-10-15)
Among patients with resected colon cancer, black patients have worse survival than whites. We investigated whether disparities in survival and related endpoints would persist when patients were treated with identical therapies in controlled clinical trials. We assessed 14,611 patients (1218
Daisuke Hasegawa et al.
The Journal of veterinary medical science, 74(11), 1517-1521 (2012-07-13)
A 9 year-old, neutered, male French Bulldog showing cluster seizures was diagnosed with a glioma in the right piriform cortex by MRI. Hypofractionated radiation therapy (RT) was performed using a linear accelerator. Although the lesion had involuted significantly at 2
Joann L Ater et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(21), 2641-2647 (2012-06-06)
PURPOSE Surgery is curative therapy for pediatric low-grade gliomas (LGGs) in areas of the brain amenable to complete resection. However, LGGs located in areas where complete resection is not possible can threaten both function and life. The purpose of this
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico